Daily Stock Analysis, KMPH, KemPharm Inc, priceseries

KemPharm Inc. Daily Stock Analysis
Stock Information
Open
0.42
Close
0.37
High
0.43
Low
0.37
Previous Close
0.41
Daily Price Gain
-0.04
YTD High
2.85
YTD High Date
Jan 22, 2019
YTD Low
0.37
YTD Low Date
Dec 6, 2019
YTD Price Change
-1.61
YTD Gain
-81.11%
52 Week High
3.00
52 Week High Date
Dec 7, 2018
52 Week Low
0.37
52 Week Low Date
Dec 6, 2019
52 Week Price Change
-2.46
52 Week Gain
-86.78%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Mar 27. 2017
4.30
Apr 10. 2017
4.58
10 Trading Days
6.55%
Link
LONG
Sep 13. 2017
3.30
Sep 29. 2017
3.72
12 Trading Days
12.68%
Link
LONG
Dec 27. 2017
3.95
Feb 5. 2018
5.78
26 Trading Days
46.44%
Link
LONG
May 10. 2018
5.30
May 30. 2018
6.19
13 Trading Days
16.76%
Link
LONG
Jan 4. 2019
2.17
Jan 31. 2019
2.66
18 Trading Days
22.65%
Link
LONG
May 16. 2019
1.33
May 31. 2019
1.60
10 Trading Days
20.64%
Link
Company Information
Stock Symbol
KMPH
Exchange
NasdaqGM
Company URL
http://www.kempharm.com
Company Phone
319-665-2575
CEO
Travis C. Mickle
Headquarters
Iowa
Business Address
2500 CROSSPARK ROAD, SUITE E126, CORALVILLE, IA 52241
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001434647
About

KemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. Its portfolio of product addresses pain, attention-deficit or hyperactivity disorder, and central nervous system. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Coralville, IA.

Description

KemPharm, Inc., a clinical-stage specialty pharmaceutical company, discovers and develops new proprietary prodrugs in the United States. Its lead product candidates are KP415, an extended release d-threo-methylphenidate product candidate for the treatment of ADHD; and KP201/IR, an IR formulation of KP201, a prodrug of hydrocodone and acetaminophen for the treatment of acute pain. The company is also involved in developing KP511/ER, a prodrug of hydromorphone for the management of pain; KP511/IR for the short duration management of acute pain; KP606/IR, an IR formulation of KP606, a prodrug of oxycodone for the management of moderate to severe pain; KP746, a prodrug of oxymorphone for the management of moderate to severe pain; and KP303, a prodrug of quetiapine for the treatment of central nervous system disorders. KemPharm, Inc. was founded in 2006 and is headquartered in Coralville, Iowa.